The purpose of this study is to determine if vaccination rate of eligible patients at a major urban public hospital will increase by having ophthalmologists screen patients for eligibility and a nurse administer the vaccine in the General Eye Clinic.

Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:

Answers to Survey Questions [ Time Frame: January 9, 2012 to February 12, 2012 ] [ Designated as safety issue: No ]

All enrolled patients completed a survey of baseline characteristics, eligibility for the herpes zoster vaccine, and attitudes regarding herpes zoster vaccination. The survey results from patients who agreed to receive the herpes zoster vaccine were compared to the results of patients who declined to be vaccinated.

Patients in this arm were eligible for the herpes zoster vaccine and chose to receive it.

Other: Choosing to receive the vaccine

No Intervention: Subjects who declined the vaccine

Detailed Description:

Patient vaccination behaviors will be assessed after 100 doses of the Zostavax vaccine are provided to underserved patients screened by ophthalmologists at the General Eye Clinic at a public hospital that does not normally provide the vaccine. A nurse will be at the clinic to administer the vaccine. Patients will be contacted by phone 1 month later and seen within 3 months in the Eye Clinic to determine whether there were any side effects.

Eligibility

Ages Eligible for Study:

60 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

60 years of age or older

Absence of evidence of immune compromise in the medical record

Ability to speak and read English, Spanish or Chinese and give informed consent

Exclusion Criteria:

Vulnerable patients, including the cognitively impaired, prisoners and employee

FDA contraindications for Zostavax vaccine

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01483378